Pyrrole-3-Carboxamides as Potent and Selective Jak2 Inhibitors.
Brasca, M.G., Nesi, M., Avanzi, N., Ballinari, D., Bandiera, T., Bertrand, J., Bindi, S., Canevari, G., Carenzi, D., Casero, D., Ceriani, L., Ciomei, M., Cirla, A., Colombo, M., Cribioli, S., Cristiani, C., Della Vedova, F., Fachin, G., Fasolini, M., Felder, E.R., Galvani, A., Isacchi, A., Mirizzi, D., Motto, I., Panzeri, A., Pesenti, E., Vianello, P., Gnocchi, P., Donati, D.(2014) Bioorg Med Chem 22: 4998
- PubMed: 25009002 
- DOI: https://doi.org/10.1016/j.bmc.2014.06.025
- Primary Citation of Related Structures:  
4D0W, 4D0X, 4D1S - PubMed Abstract: 
We report herein the discovery, structure guided design, synthesis and biological evaluation of a novel class of JAK2 inhibitors. Optimization of the series led to the identification of the potent and orally bioavailable JAK2 inhibitor 28 (NMS-P953). Compound 28 displayed significant tumour growth inhibition in SET-2 xenograft tumour model, with a mechanism of action confirmed in vivo by typical modulation of known biomarkers, and with a favourable pharmacokinetic and safety profile.
Organizational Affiliation: 
Nerviano Medical Sciences S.r.l., Oncology, Viale Pasteur 10, 20014 Nerviano (MI), Italy. Electronic address: gabriella.brasca@nervianoms.com.